KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Cash from Financing Activities (2016 - 2023)

Historic Cash from Financing Activities for TherapeuticsMD (TXMD) over the last 13 years, with Q4 2023 value amounting to $2.0 million.

  • TherapeuticsMD's Cash from Financing Activities rose 10178.84% to $2.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$108.2 million, marking a year-over-year increase of 5399.56%. This contributed to the annual value of $3.2 million for FY2023, which is 10133.97% up from last year.
  • Latest data reveals that TherapeuticsMD reported Cash from Financing Activities of $2.0 million as of Q4 2023, which was up 10178.84% from -$1000.0 recorded in Q3 2023.
  • Over the past 5 years, TherapeuticsMD's Cash from Financing Activities peaked at $111.7 million during Q2 2019, and registered a low of -$120.0 million during Q2 2022.
  • In the last 5 years, TherapeuticsMD's Cash from Financing Activities had a median value of $890500.0 in 2021 and averaged $9.2 million.
  • As far as peak fluctuations go, TherapeuticsMD's Cash from Financing Activities surged by 4866981.63% in 2020, and later tumbled by 2813738.32% in 2022.
  • Over the past 5 years, TherapeuticsMD's Cash from Financing Activities (Quarter) stood at $77.0 million in 2019, then crashed by 58.84% to $31.7 million in 2020, then tumbled by 95.73% to $1.4 million in 2021, then plummeted by 8373.84% to -$111.9 million in 2022, then soared by 101.79% to $2.0 million in 2023.
  • Its last three reported values are $2.0 million in Q4 2023, -$1000.0 for Q3 2023, and -$111.9 million during Q4 2022.